See what are your chances of getting this job! About the role
Overview
We are looking for a strategic and data-driven Head of Operations to lead and scale the operational engine behind our decentralized exchange (DEX), focusing on user growth, product optimization, and cross-functional team coordination.
Skills
Candidate requirements
These are the minimum requirements a candidate must meet to be considered for this role.
- 3+ years in growth/ops leadership roles in Web3, fintech, or tech startups.
- Proven success managing user acquisition and product iteration in DeFi or trading-related platforms.
Head of Operations (Web3 DEX)
Unleashing the Power of mRNA and AI for Cancer Diagnostics
Last updated 2025-08-01T23:00:52.877Z
Overview
We are looking for a strategic and data-driven Head of Operations to lead and scale the operational engine behind our decentralized exchange (DEX), focusing on user growth, product optimization, and cross-functional team coordination.
Salary
$60,000 - $84,000
/yearLocation
Onsite
Department
Operations & Strategy
Level
Skills
Overview
We are looking for a strategic and data-driven Head of Operations to lead and scale the operational engine behind our decentralized exchange (DEX), focusing on user growth, product optimization, and cross-functional team coordination.
Skills
Candidate requirements
These are the minimum requirements a candidate must meet to be considered for this role.
- 3+ years in growth/ops leadership roles in Web3, fintech, or tech startups.
- Proven success managing user acquisition and product iteration in DeFi or trading-related platforms.
About Wren Laboratories
Wren Laboratories is revolutionizing cancer diagnostics with advanced machine learning and liquid biopsy mRNA-based technology. Our goal is to provide precise, non-invasive diagnostics tailored to each patient's unique molecular profile, transforming early detection and surveillance of cancer for better patient outcomes.
With over 100 patents and validation from more than 60 clinical studies, Wren has developed highly sensitive liquid biopsy mRNA gene expression-based assays. These innovative assays aid in cancer diagnosis, detect minimal residual disease (MRD), and predict tumor prognosis and therapeutic response.
Our tests, including the NETest for neuroendocrine tumors and PROSTest for prostate cancer, leverage mRNA technology and AI/ML genomic assays for unparalleled molecular insights. This allows accurate detection of cancer markers, empowering personalized care. Our mRNA-based diagnostics are crucial in monitoring patients post-surgery or treatment.
Wren also offers Biopharma services with AI/ML liquid biopsy genomic assays for research and companion diagnostics (CDx) development. Our RNA stabilizer tubes preserve whole blood at ambient temperature for up to 10 days, reducing clinical trial logistics.
From our CLIA-certified, CAP-accredited, and NYS-licensed lab, our tests ensure high accuracy and reliability. For more information, visit our website and follow us for updates in non-invasive cancer diagnostics.
Company score (5)
Most candidates are reviewed quickly